
Perkirol0.25 mg
Square Pharmaceuticals PLC.
Ropinirole is a non-ergot dopamine agonist used in the following settings: Established / FDA-approved uses Idiopathic Parkinson's disease - as monotherapy in early disease and more.
Ropinirole is a non-ergot dopamine agonist used in the following settings:
| Week | Dose |
|---|---|
| Week 1 | 0.25 mg three times daily |
| Week 2 | 0.5 mg three times daily |
| Week 3 | 0.75 mg three times daily |
| Week 4 | 1 mg three times daily |
After week 4, the daily dose may be increased by up to 1.5 mg/day on a weekly basis up to a dose of 9 mg/day, then by up to 3 mg/day weekly, to a usual maintenance range of 3-24 mg/day in three divided doses, individualized to response and tolerability. Ropinirole should be tapered gradually rather than stopped abruptly (see Precautions).
Initial dose: 2 mg once daily for 1-2 weeks, then increased in increments of 2 mg/day at weekly or longer intervals, up to a usual maintenance range of 2-24 mg once daily, based on response and tolerability. Extended-release tablets must be swallowed whole.
| Timing | Dose |
|---|---|
| Day 1-2 | 0.25 mg once daily, 1-3 hours before bedtime |
| Day 3-7 | 0.5 mg once daily |
| Week 2 | 0.75 mg once daily |
| Week 3 | 1 mg once daily |
Dose may be titrated further thereafter if needed, up to a maximum of 4 mg once daily. Doses higher than those studied for RLS have not shown added benefit and increase the risk of augmentation (see Precautions).
Ropinirole has not been well studied in hepatic impairment; since it is extensively metabolized by the liver, use with caution and consider a lower starting dose and slower titration in patients with hepatic impairment.
No dose adjustment is generally needed in mild-to-moderate renal impairment. Use in severe renal impairment or in patients on dialysis has not been well studied for the immediate-release product and is not recommended for the extended-release product; specialist guidance is required.
If a dose of Ropinirole is missed, it should generally be skipped and the next dose taken at the usual time rather than doubling up, unless a physician advises otherwise. Ropinirole must never be stopped abruptly (see Precautions).
Ropinirole is contraindicated in patients with known hypersensitivity to Ropinirole or any component of the formulation. There are no other well-established absolute contraindications; conditions such as hepatic or renal impairment, elderly age, or a history of psychiatric symptoms require caution and dose adjustment rather than avoidance (see Precautions and Use in Special Populations).
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.